Pfs25-IMX313
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Pfs25-IMX313, covering 2026-02-23 to 2026-02-23. Get the full timeline:
Most recent: Clinical Trial Update: Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant [Phase 1, Phase 2]